Addex Therapeutics Ltd
NASDAQ:ADXN
Addex Therapeutics Ltd
NASDAQ:ADXN
Price:
6.2197
USD
9.89%
Market Cap:
$6.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
CH |
|
D
|
Duke Energy Corp
F:D2MN
|
US |
|
Knightscope Inc
NASDAQ:KSCP
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Hard Off Corporation Co Ltd
TSE:2674
|
JP |
|
SK Rosgosstrakh PAO
MOEX:RGSS
|
RU |
|
Sanken Electric Co Ltd
OTC:SANJF
|
JP |
|
D
|
Delta Corp Ltd
NSE:DELTACORP
|
IN |
|
A
|
AVIC Electromechanical Systems Co Ltd
SZSE:002013
|
CN |
|
K
|
Kontigo Care AB
STO:KONT
|
SE |
|
Graham Corp
NYSE:GHM
|
US |
|
Vienna Insurance Group AG Wiener Versicherung Gruppe
OTC:VNRGF
|
AT |
|
P
|
Prakash Pipes Ltd
BSE:542684
|
IN |
|
S
|
Sidiz Inc
KRX:134790
|
KR |
|
Ontex Group NV
XBRU:ONTEX
|
BE |
|
J
|
Japan Foundation Engineering Co Ltd
TSE:1914
|
JP |
|
C
|
Central Vietnam Metal Corp
VN:KMT
|
VN |
Relative Value
The Relative Value of one
ADXN
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 6.2197 USD,
Addex Therapeutics Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ADXN Relative Value
HIDDEN
Multiples Across Competitors
ADXN Competitors Multiples
Addex Therapeutics Ltd Competitors
Addex Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
7.2m USD | 12.5 | -1.2 | -2.4 | -2.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.3B USD | 5.9 | 86.2 | 14.4 | 19.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.4B USD | 5.8 | 20.1 | 12.6 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.6B USD | 9.5 | 28.8 | 21.6 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.9B USD | 5.5 | 17.4 | 12.9 | 14.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.2 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.1 | 32.5 | 35 | 35.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
